Skip to main content
Evidence Snapshot

Sodium channel protein type 2 subunit alpha

CHEMBL3399 SINGLE PROTEIN Rattus norvegicus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3399
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Sodium channel protein type 2 subunit alpha as ChEMBL target CHEMBL3399, mapped to UniProt P04775. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Sodium channel protein type 2 subunit alpha
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL3399
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P04775
Sodium channel protein type 2 subunit alpha
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Sodium channel protein type 2 subunit alpha matters

As of 2026-09-13

Sodium channel protein type 2 subunit alpha is reviewed as Sodium channel protein type 2 subunit alpha (UniProt P04775); the current evidence base includes 6 approved drugs, 185 compounds, and 34 assays, with lead potency reaching pChEMBL 8.6.

Protein context
Sodium channel protein type 2 subunit alpha

Sodium channel protein type 2 subunit alpha Sequence length is 2005 aa.

Review this target as Sodium channel protein type 2 subunit alpha, mapped to UniProt P04775. Sequence length is 2005 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P04775 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 6 approved drugs, 185 compounds, and 34 assays for this target. The dominant activity type is IC50. CHEMBL3318149 is the current potency anchor at pChEMBL 8.6.

Use CHEMBL3318149 as the tractability anchor when discussing potency (pChEMBL 8.6).

Activity source · ChEMBL 36 via Core Engine
6 approved pChEMBL 8.6
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Sodium channel protein type 2 subunit alpha matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P04775, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

185
Total Compounds
34
Total Assays
6
Approved Drugs
IC50: 122.0, KI: 1.0, EC50: 7.0, KD: 8.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3318149
 8.6 IC50 —
No preferred name
CHEMBL525818
 8.5 Kd —
No preferred name
CHEMBL3318150
 8.5 IC50 —
No preferred name
CHEMBL3318148
 8.5 IC50 —
No preferred name
CHEMBL507974
 8.4 IC50 Clinical

Approved Drugs

Structure Compound First Approval
MIBEFRADIL
CHEMBL45816
 1997
PIMOZIDE
CHEMBL1423
 1984
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3399